VTGN — Vistagen Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.97m
- -$23.76m
- $1.27m
U.S. STOCKS ON THE MOVE-Wyndham Hotels, Johnson & Johnson, NetScout
Vistagen jumps after Citadel founder Ken Griffin discloses stake
Brief: Kenneth Griffin Reports 5.7% Passive Stake In Vistagen Therapeutics As Of October 4 - SEC Filing
Brief: Point72 Asset Management, L.P Reports 5.6% Passive Stake In Vistagen Therapeutics, Inc. As Of October 4- SEC Filing
Brief: Vistagen Announces Pricing Of $100 Million Underwritten Offering
Brief: Vistagen Therapeutics Says PH80 Was Well-Tolerated With Adverse Event Profile Similar To Placebo
Brief: Vistagen And Fuji Enter Exclusive Negotiation Agreement For A Potential License To Develop And Commercialize Vistagen’S Investigational Menopausal Hot Flash Therapy, Ph80 Nasal Spray, In Japan
U.S. STOCKS ON THE MOVE-AppLovin, SolarEdge, Fabrinet
Vistagen Therapeutics names new CFO, shares rise
Brief: Vistagen Appoints Cindy Anderson As Chief Financial Officer
Brief: Commodore Capital LP in SEC Filing Reports 19.7% Passive Stake In Vistagen Therapeutics As Of Aug 7
U.S. STOCKS ON THE MOVE-Warner Bros, Green Plains, Tyson Foods
U.S. STOCKS ON THE MOVE-PayPal, Vistagen, Save Foods
Brief: Vistagen Announces Positive Top-Line Results From Phase 3 Palisade-2 Trial Of Fasedienol Nasal Spray In Social Anxiety Disorder
Vistagen skyrockets as social anxiety disorder drug succeeds in late stage study
Brief: VistaGen Reports Preclinical Data Supporting Itruvone (Ph10) Nasal Spray’S Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry Into The Brain
Brief: Vistagen Receives Notice Of Allowance For Av-101 Canadian Patent For Treatment Of Dyskinesia Related To Levodopa Therapy For Parkinson’S Disease
Brief: Vistagen Therapeutics Jerrold Dotson, CFO Intends To Retire From Co On Or About Aug 31
Vistagen Therapeutics Inc reports results for the quarter ended in March - Earnings Summary